{
  "hash": "61a2a5149f32cbdf79c7587bb7709cba",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: \"Mammella — Casi MTB (HR+/HER2− e TNBC)\"\n---\n\n::: {.cell}\n\n```{.r .cell-code}\nlibrary(readr); library(dplyr); library(gt); library(stringr); library(tidyr)\n\n# ===== Helpers per robustezza =====\nstandardize_cols <- function(df) {\n  mapping <- list(\n    case                = c(\"case\",\"Case\",\"cohort\",\"subset\",\"Group\",\"group\"),\n    gene                = c(\"gene\",\"Gene\",\"Hugo_Symbol\",\"Symbol\"),\n    variant             = c(\"variant\",\"Variant\",\"cDNA\",\"cdna_change\",\"hgvsc\",\"hgvsc_short\",\"c_change\",\"mutation\",\"c_variant\",\"c_hgvs\"),\n    protein_change      = c(\"protein_change\",\"Protein\",\"hgvsp\",\"hgvsp_short\",\"p_change\",\"aa_change\",\"p_hgvs\",\"protein\"),\n    effect              = c(\"consequence\",\"effect\",\"variant_effect\",\"Consequence\"),\n    classification      = c(\"classification\",\"class\",\"pathogenicity\",\"clin_sig\",\"clinical_significance\",\"significance\"),\n    escat               = c(\"escat\",\"ESCAT\"),\n    tier_amp_asco_cap   = c(\"tier_amp_asco_cap\",\"tier\",\"tier_amp\",\"amp_asco_cap_tier\",\"amp_asco_cap\"),\n    vaf                 = c(\"vaf\",\"VAF\",\"allele_fraction\",\"variant_allele_frequency\",\"AF\"),\n    depth               = c(\"depth\",\"coverage\",\"dp\",\"read_depth\",\"DP\"),\n    pd_l1_cps           = c(\"pd_l1_cps\",\"PDL1_CPS\",\"PDL1\",\"pd-l1\",\"pdl1\"),\n    msi_status          = c(\"msi_status\",\"MSI\",\"msi\",\"mismatch_repair\"),\n    tmb                 = c(\"tmb\",\"TMB\",\"tumor_mutational_burden\",\"mutational_burden\"),\n    her2_ihc            = c(\"her2_ihc\",\"HER2_IHC\",\"ihc_her2\"),\n    her2_ish            = c(\"her2_ish\",\"HER2_ISH\",\"fish_her2\"),\n    notes               = c(\"notes\",\"note\",\"comment\",\"comments\",\"interpretation\",\"report_note\")\n  )\n  for (tgt in names(mapping)) {\n    hit <- mapping[[tgt]][mapping[[tgt]] %in% names(df)]\n    if (length(hit) >= 1) df[[tgt]] <- df[[hit[1]]] else df[[tgt]] <- NA\n  }\n  df\n}\n\n# carica dati\nsom1  <- read_csv(\"data/breast_variants_somatic.csv\", show_col_types = FALSE) \nsom <- som1 %>%\n  rename(\n    variant         = variant_cDNA,\n    protein_change  = variant_protein,\n    tier_amp_asco_cap = tier_amp_ascocap,   # corregge il typo\n    notes           = evidence_summary\n  ) %>%\n  mutate(\n    VAF        = suppressWarnings(as.numeric(vaf)),\n    Copertura  = suppressWarnings(as.numeric(depth))\n  )\n\n# (opzionale) se vuoi tenere anche le copy-number in tabella\n# le rinominiamo in \"CN\" per chiarezza:\nif (\"copy_number\" %in% names(som)) {\n  som <- som %>% rename(CN = copy_number)\n}\n\n# ---- FUNZIONE TABELLA ROBUSTA ----\nmk_table <- function(df, caption) {\n  # seleziona solo le colonne che esistono\n  disp <- df %>%\n    select(any_of(c(\n      \"gene\",\"variant\",\"protein_change\",\"effect\",\"CN\",\n      \"escat\",\"tier_amp_asco_cap\",\"VAF\",\"Copertura\",\"notes\"\n    ))) %>%\n    rename(\n      Gene      = gene,\n      Variante  = variant,\n      Proteina  = protein_change,\n      Effetto   = effect,\n      ESCAT     = escat,\n      Tier      = tier_amp_asco_cap,\n      Note      = notes\n    )\n\n  gt(disp) |>\n    tab_caption(caption) |>\n    fmt_number(columns = any_of(c(\"VAF\")), decimals = 3) |>\n    tab_spanner(label = \"Qualità\", columns = intersect(c(\"VAF\",\"Copertura\"), names(disp))) |>\n    tab_source_note(md(\"**Nota**: VAF/Copertura mostrate solo se presenti.\"))\n}\n\nsom<-som |> standardize_cols()\n\ngerm <- read_csv(\"data/breast_variants_germline.csv\", show_col_types = FALSE) |> standardize_cols()\n\n# coerenza tipi numerici dove esistono\nsom <- som |>\n  mutate(vaf_num = suppressWarnings(as.numeric(vaf)),\n         depth_num = suppressWarnings(as.numeric(depth)),\n         tmb_num = suppressWarnings(as.numeric(tmb)),\n         pd_l1_cps_num = suppressWarnings(as.numeric(pd_l1_cps)))\n\ngerm <- germ %>%\n  # crea le colonne numeriche solo se quelle originali esistono\n  mutate(across(any_of(c(\"vaf\",\"depth\")),\n                ~ suppressWarnings(as.numeric(.x)),\n                .names = \"{.col}_num\"))  #suppressWarnings(as.numeric(depth)) else NA_real_)\n\n# utility per rendering tabella pulita (funziona anche se VAF/Depth non esistono)\nmk_table <- function(df, caption) {\n  # assicura colonne opzionali\n  if (!(\"vaf_num\" %in% names(df)))   df$vaf_num <- NA_real_\n  if (!(\"depth_num\" %in% names(df))) df$depth_num <- NA_real_\n  disp <- df |>\n    select(any_of(c(\"gene\",\"variant\",\"protein_change\",\"effect\",\"classification\",\n                    \"escat\",\"tier_amp_asco_cap\",\"vaf_num\",\"depth_num\",\"notes\"))) |>\n    rename(Gene = gene, Variante = variant, Proteina = protein_change, Effetto = effect,\n           Classe = classification, ESCAT = escat, Tier = tier_amp_asco_cap,\n           VAF = vaf_num, Copertura = depth_num, Note = notes)\n  gt(disp) |>\n    tab_caption(caption) |>\n    fmt_number(columns = c(\"VAF\"), decimals = 3) |>\n    tab_spanner(label = \"Qualità\", columns = c(\"VAF\",\"Copertura\")) |>\n    tab_source_note(md(\"**Nota**: VAF e copertura sono riportate solo se presenti nei file sorgente.\"))\n}\n```\n:::\n\n\n\n\n\n------------------------------------------------------------------------\n\n## HR+/HER2− — Varianti di interesse\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code}\nsom %>% filter(case %in% c(\"HRpos_HER2neg\",\"HR+_HER2-\",\"HRpos\")) %>% select(-any_of(\"case\")) %>%\n  mk_table(\"HR+/HER2− — Varianti somatiche\")\n```\n\n::: {.cell-output-display}\n\n```{=html}\n<div id=\"jdmobiqjzv\" style=\"padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;\">\n<style>#jdmobiqjzv table {\n  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';\n  -webkit-font-smoothing: antialiased;\n  -moz-osx-font-smoothing: grayscale;\n}\n\n#jdmobiqjzv thead, #jdmobiqjzv tbody, #jdmobiqjzv tfoot, #jdmobiqjzv tr, #jdmobiqjzv td, #jdmobiqjzv th {\n  border-style: none;\n}\n\n#jdmobiqjzv p {\n  margin: 0;\n  padding: 0;\n}\n\n#jdmobiqjzv .gt_table {\n  display: table;\n  border-collapse: collapse;\n  line-height: normal;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_caption {\n  padding-top: 4px;\n  padding-bottom: 4px;\n}\n\n#jdmobiqjzv .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#jdmobiqjzv .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 3px;\n  padding-bottom: 5px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#jdmobiqjzv .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#jdmobiqjzv .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#jdmobiqjzv .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#jdmobiqjzv .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#jdmobiqjzv .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#jdmobiqjzv .gt_spanner_row {\n  border-bottom-style: hidden;\n}\n\n#jdmobiqjzv .gt_group_heading {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  text-align: left;\n}\n\n#jdmobiqjzv .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#jdmobiqjzv .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#jdmobiqjzv .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#jdmobiqjzv .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#jdmobiqjzv .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jdmobiqjzv .gt_stub_row_group {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n  vertical-align: top;\n}\n\n#jdmobiqjzv .gt_row_group_first td {\n  border-top-width: 2px;\n}\n\n#jdmobiqjzv .gt_row_group_first th {\n  border-top-width: 2px;\n}\n\n#jdmobiqjzv .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jdmobiqjzv .gt_first_summary_row {\n  border-top-style: solid;\n  border-top-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_first_summary_row.thick {\n  border-top-width: 2px;\n}\n\n#jdmobiqjzv .gt_last_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jdmobiqjzv .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_last_grand_summary_row_top {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: double;\n  border-bottom-width: 6px;\n  border-bottom-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#jdmobiqjzv .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jdmobiqjzv .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#jdmobiqjzv .gt_sourcenote {\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jdmobiqjzv .gt_left {\n  text-align: left;\n}\n\n#jdmobiqjzv .gt_center {\n  text-align: center;\n}\n\n#jdmobiqjzv .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#jdmobiqjzv .gt_font_normal {\n  font-weight: normal;\n}\n\n#jdmobiqjzv .gt_font_bold {\n  font-weight: bold;\n}\n\n#jdmobiqjzv .gt_font_italic {\n  font-style: italic;\n}\n\n#jdmobiqjzv .gt_super {\n  font-size: 65%;\n}\n\n#jdmobiqjzv .gt_footnote_marks {\n  font-size: 75%;\n  vertical-align: 0.4em;\n  position: initial;\n}\n\n#jdmobiqjzv .gt_asterisk {\n  font-size: 100%;\n  vertical-align: 0;\n}\n\n#jdmobiqjzv .gt_indent_1 {\n  text-indent: 5px;\n}\n\n#jdmobiqjzv .gt_indent_2 {\n  text-indent: 10px;\n}\n\n#jdmobiqjzv .gt_indent_3 {\n  text-indent: 15px;\n}\n\n#jdmobiqjzv .gt_indent_4 {\n  text-indent: 20px;\n}\n\n#jdmobiqjzv .gt_indent_5 {\n  text-indent: 25px;\n}\n\n#jdmobiqjzv .katex-display {\n  display: inline-flex !important;\n  margin-bottom: 0.75em !important;\n}\n\n#jdmobiqjzv div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {\n  height: 0px !important;\n}\n</style>\n<table class=\"gt_table\" data-quarto-disable-processing=\"false\" data-quarto-bootstrap=\"false\">\n  <caption>HR+/HER2− — Varianti somatiche</caption>\n  <thead>\n    <tr class=\"gt_col_headings gt_spanner_row\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Gene\">Gene</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Variante\">Variante</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Proteina\">Proteina</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Effetto\">Effetto</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Classe\">Classe</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"ESCAT\">ESCAT</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Tier\">Tier</th>\n      <th class=\"gt_center gt_columns_top_border gt_column_spanner_outer\" rowspan=\"1\" colspan=\"2\" scope=\"colgroup\" id=\"Qualità\">\n        <div class=\"gt_column_spanner\">Qualità</div>\n      </th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Note\">Note</th>\n    </tr>\n    <tr class=\"gt_col_headings\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"VAF\">VAF</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"Copertura\">Copertura</th>\n    </tr>\n  </thead>\n  <tbody class=\"gt_table_body\">\n    <tr><td headers=\"Gene\" class=\"gt_row gt_left\">PIK3CA</td>\n<td headers=\"Variante\" class=\"gt_row gt_left\">c.3140A&gt;G</td>\n<td headers=\"Proteina\" class=\"gt_row gt_left\">p.H1047R</td>\n<td headers=\"Effetto\" class=\"gt_row gt_left\">Activating</td>\n<td headers=\"Classe\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"ESCAT\" class=\"gt_row gt_left\">I-A</td>\n<td headers=\"Tier\" class=\"gt_row gt_left\">Tier IA</td>\n<td headers=\"VAF\" class=\"gt_row gt_right\">0.310</td>\n<td headers=\"Copertura\" class=\"gt_row gt_right\">480</td>\n<td headers=\"Note\" class=\"gt_row gt_left\">Enables PI3K inhibitor (alpelisib) with endocrine therapy.</td></tr>\n    <tr><td headers=\"Gene\" class=\"gt_row gt_left\">ESR1</td>\n<td headers=\"Variante\" class=\"gt_row gt_left\">c.1610A&gt;C</td>\n<td headers=\"Proteina\" class=\"gt_row gt_left\">p.Y537S</td>\n<td headers=\"Effetto\" class=\"gt_row gt_left\">Activating</td>\n<td headers=\"Classe\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"ESCAT\" class=\"gt_row gt_left\">II</td>\n<td headers=\"Tier\" class=\"gt_row gt_left\">Tier IIA</td>\n<td headers=\"VAF\" class=\"gt_row gt_right\">0.120</td>\n<td headers=\"Copertura\" class=\"gt_row gt_right\">420</td>\n<td headers=\"Note\" class=\"gt_row gt_left\">Resistance marker; SERD consideration.</td></tr>\n  </tbody>\n  <tfoot class=\"gt_sourcenotes\">\n    <tr>\n      <td class=\"gt_sourcenote\" colspan=\"10\"><span data-qmd-base64=\"KipOb3RhKio6IFZBRiBlIGNvcGVydHVyYSBzb25vIHJpcG9ydGF0ZSBzb2xvIHNlIHByZXNlbnRpIG5laSBmaWxlIHNvcmdlbnRlLg==\"><span class='gt_from_md'><strong>Nota</strong>: VAF e copertura sono riportate solo se presenti nei file sorgente.</span></span></td>\n    </tr>\n  </tfoot>\n  \n</table>\n</div>\n```\n\n:::\n:::\n\n\n\n\n\n### Suggerimenti clinici (HR+/HER2−, aggiornati al 2025)\n\n-   **ESR1 mutato** → **elacestrant (SERD orale)** in progressione a ET/CDK4/6 **se ESR1+** (test liquido o tessuto con CDx). \\[FDA 27-01-2023\\]\\\n    *Note*: utilità maggiore dopo **CDK4/6i** e in malattia sensibile all’ET.\\\n-   **PIK3CA/AKT1/PTEN alterati** → **capivasertib + fulvestrant** (post-ET) **o** **alpelisib + ET** per **PIK3CA mut** selezionate.\\\n-   **HER2-low (IHC 1+ o 2+/ISH−)** → nelle linee successive, considerare **trastuzumab deruxtecan (T‑DXd)**.\\\n-   **MSI‑H/TMB‑high** (raro) → opzione **pembrolizumab** *tissue‑agnostic*.\\\n-   **NTRK fusion** (rarissimo) → **larotrectinib** o **entrectinib**.\n\n> Razionale/Fonti principali: ESMO Living Guideline 2025 HR+/HER2−; FDA label **elacestrant**; FDA label **capivasertib**; DESTINY‑Breast04 per **T‑DXd**.\n\n------------------------------------------------------------------------\n\n## TNBC — Varianti di interesse\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code}\nsom %>% filter(case %in% c(\"TNBC\",\"TripleNegative\")) %>% select(-any_of(\"case\")) %>%\n  mk_table(\"TNBC — Varianti somatiche\")\n```\n\n::: {.cell-output-display}\n\n```{=html}\n<div id=\"ejbeaecuyf\" style=\"padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;\">\n<style>#ejbeaecuyf table {\n  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';\n  -webkit-font-smoothing: antialiased;\n  -moz-osx-font-smoothing: grayscale;\n}\n\n#ejbeaecuyf thead, #ejbeaecuyf tbody, #ejbeaecuyf tfoot, #ejbeaecuyf tr, #ejbeaecuyf td, #ejbeaecuyf th {\n  border-style: none;\n}\n\n#ejbeaecuyf p {\n  margin: 0;\n  padding: 0;\n}\n\n#ejbeaecuyf .gt_table {\n  display: table;\n  border-collapse: collapse;\n  line-height: normal;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_caption {\n  padding-top: 4px;\n  padding-bottom: 4px;\n}\n\n#ejbeaecuyf .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#ejbeaecuyf .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 3px;\n  padding-bottom: 5px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#ejbeaecuyf .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#ejbeaecuyf .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#ejbeaecuyf .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#ejbeaecuyf .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#ejbeaecuyf .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#ejbeaecuyf .gt_spanner_row {\n  border-bottom-style: hidden;\n}\n\n#ejbeaecuyf .gt_group_heading {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  text-align: left;\n}\n\n#ejbeaecuyf .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ejbeaecuyf .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#ejbeaecuyf .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#ejbeaecuyf .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#ejbeaecuyf .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ejbeaecuyf .gt_stub_row_group {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n  vertical-align: top;\n}\n\n#ejbeaecuyf .gt_row_group_first td {\n  border-top-width: 2px;\n}\n\n#ejbeaecuyf .gt_row_group_first th {\n  border-top-width: 2px;\n}\n\n#ejbeaecuyf .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ejbeaecuyf .gt_first_summary_row {\n  border-top-style: solid;\n  border-top-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_first_summary_row.thick {\n  border-top-width: 2px;\n}\n\n#ejbeaecuyf .gt_last_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ejbeaecuyf .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_last_grand_summary_row_top {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: double;\n  border-bottom-width: 6px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#ejbeaecuyf .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ejbeaecuyf .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ejbeaecuyf .gt_sourcenote {\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ejbeaecuyf .gt_left {\n  text-align: left;\n}\n\n#ejbeaecuyf .gt_center {\n  text-align: center;\n}\n\n#ejbeaecuyf .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#ejbeaecuyf .gt_font_normal {\n  font-weight: normal;\n}\n\n#ejbeaecuyf .gt_font_bold {\n  font-weight: bold;\n}\n\n#ejbeaecuyf .gt_font_italic {\n  font-style: italic;\n}\n\n#ejbeaecuyf .gt_super {\n  font-size: 65%;\n}\n\n#ejbeaecuyf .gt_footnote_marks {\n  font-size: 75%;\n  vertical-align: 0.4em;\n  position: initial;\n}\n\n#ejbeaecuyf .gt_asterisk {\n  font-size: 100%;\n  vertical-align: 0;\n}\n\n#ejbeaecuyf .gt_indent_1 {\n  text-indent: 5px;\n}\n\n#ejbeaecuyf .gt_indent_2 {\n  text-indent: 10px;\n}\n\n#ejbeaecuyf .gt_indent_3 {\n  text-indent: 15px;\n}\n\n#ejbeaecuyf .gt_indent_4 {\n  text-indent: 20px;\n}\n\n#ejbeaecuyf .gt_indent_5 {\n  text-indent: 25px;\n}\n\n#ejbeaecuyf .katex-display {\n  display: inline-flex !important;\n  margin-bottom: 0.75em !important;\n}\n\n#ejbeaecuyf div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {\n  height: 0px !important;\n}\n</style>\n<table class=\"gt_table\" data-quarto-disable-processing=\"false\" data-quarto-bootstrap=\"false\">\n  <caption>TNBC — Varianti somatiche</caption>\n  <thead>\n    <tr class=\"gt_col_headings gt_spanner_row\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Gene\">Gene</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Variante\">Variante</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Proteina\">Proteina</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Effetto\">Effetto</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Classe\">Classe</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"ESCAT\">ESCAT</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Tier\">Tier</th>\n      <th class=\"gt_center gt_columns_top_border gt_column_spanner_outer\" rowspan=\"1\" colspan=\"2\" scope=\"colgroup\" id=\"Qualità\">\n        <div class=\"gt_column_spanner\">Qualità</div>\n      </th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Note\">Note</th>\n    </tr>\n    <tr class=\"gt_col_headings\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"VAF\">VAF</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"Copertura\">Copertura</th>\n    </tr>\n  </thead>\n  <tbody class=\"gt_table_body\">\n    <tr><td headers=\"Gene\" class=\"gt_row gt_left\">BRCA1</td>\n<td headers=\"Variante\" class=\"gt_row gt_left\">c.5266dupC</td>\n<td headers=\"Proteina\" class=\"gt_row gt_left\">p.Gln1756Profs*74</td>\n<td headers=\"Effetto\" class=\"gt_row gt_left\">Pathogenic (LOF)</td>\n<td headers=\"Classe\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"ESCAT\" class=\"gt_row gt_left\">I-A</td>\n<td headers=\"Tier\" class=\"gt_row gt_left\">Tier IA</td>\n<td headers=\"VAF\" class=\"gt_row gt_right\">0.440</td>\n<td headers=\"Copertura\" class=\"gt_row gt_right\">500</td>\n<td headers=\"Note\" class=\"gt_row gt_left\">PARP inhibitor eligibility in germline carriers.</td></tr>\n  </tbody>\n  <tfoot class=\"gt_sourcenotes\">\n    <tr>\n      <td class=\"gt_sourcenote\" colspan=\"10\"><span data-qmd-base64=\"KipOb3RhKio6IFZBRiBlIGNvcGVydHVyYSBzb25vIHJpcG9ydGF0ZSBzb2xvIHNlIHByZXNlbnRpIG5laSBmaWxlIHNvcmdlbnRlLg==\"><span class='gt_from_md'><strong>Nota</strong>: VAF e copertura sono riportate solo se presenti nei file sorgente.</span></span></td>\n    </tr>\n  </tfoot>\n  \n</table>\n</div>\n```\n\n:::\n:::\n\n\n\n\n\n### Suggerimenti clinici (TNBC, aggiornati al 2025)\n\n-   **PD‑L1 CPS ≥10 (prima linea metastatica)** → **pembrolizumab + chemioterapia** (KEYNOTE‑355).\\\n-   **Dopo ≥1 linea** (HR−/HER2−): **sacituzumab govitecan (Trop‑2 ADC)** ha dimostrato **beneficio OS** vs TPC.\\\n-   **gBRCA1/2** → **PARP inibitori** (olaparib/talazoparib).\\\n-   **HER2‑low** (sottogruppo di TNBC) → candidabile a **T‑DXd** in linee successive.\\\n-   **NTRK fusions** (raro) → **larotrectinib/entrectinib**.\\\n-   **MSI‑H/TMB‑high** → **pembrolizumab** *tissue‑agnostic*.\n\n> Razionale/Fonti principali: KEYNOTE‑355 per **pembrolizumab**; **ASCENT/TROPiCS‑02** e aggiornamenti 2025 per **sacituzumab govitecan**; DESTINY‑Breast04 per **T‑DXd**.\n\n------------------------------------------------------------------------\n\n## Germinale\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code}\nmk_table(germ, \"Mammella — Varianti germinali\")\n```\n\n::: {.cell-output-display}\n\n```{=html}\n<div id=\"xhvcqolqtv\" style=\"padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;\">\n<style>#xhvcqolqtv table {\n  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';\n  -webkit-font-smoothing: antialiased;\n  -moz-osx-font-smoothing: grayscale;\n}\n\n#xhvcqolqtv thead, #xhvcqolqtv tbody, #xhvcqolqtv tfoot, #xhvcqolqtv tr, #xhvcqolqtv td, #xhvcqolqtv th {\n  border-style: none;\n}\n\n#xhvcqolqtv p {\n  margin: 0;\n  padding: 0;\n}\n\n#xhvcqolqtv .gt_table {\n  display: table;\n  border-collapse: collapse;\n  line-height: normal;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_caption {\n  padding-top: 4px;\n  padding-bottom: 4px;\n}\n\n#xhvcqolqtv .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#xhvcqolqtv .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 3px;\n  padding-bottom: 5px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#xhvcqolqtv .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#xhvcqolqtv .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#xhvcqolqtv .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#xhvcqolqtv .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#xhvcqolqtv .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#xhvcqolqtv .gt_spanner_row {\n  border-bottom-style: hidden;\n}\n\n#xhvcqolqtv .gt_group_heading {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  text-align: left;\n}\n\n#xhvcqolqtv .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#xhvcqolqtv .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#xhvcqolqtv .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#xhvcqolqtv .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#xhvcqolqtv .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xhvcqolqtv .gt_stub_row_group {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n  vertical-align: top;\n}\n\n#xhvcqolqtv .gt_row_group_first td {\n  border-top-width: 2px;\n}\n\n#xhvcqolqtv .gt_row_group_first th {\n  border-top-width: 2px;\n}\n\n#xhvcqolqtv .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xhvcqolqtv .gt_first_summary_row {\n  border-top-style: solid;\n  border-top-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_first_summary_row.thick {\n  border-top-width: 2px;\n}\n\n#xhvcqolqtv .gt_last_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xhvcqolqtv .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_last_grand_summary_row_top {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: double;\n  border-bottom-width: 6px;\n  border-bottom-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#xhvcqolqtv .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xhvcqolqtv .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#xhvcqolqtv .gt_sourcenote {\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xhvcqolqtv .gt_left {\n  text-align: left;\n}\n\n#xhvcqolqtv .gt_center {\n  text-align: center;\n}\n\n#xhvcqolqtv .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#xhvcqolqtv .gt_font_normal {\n  font-weight: normal;\n}\n\n#xhvcqolqtv .gt_font_bold {\n  font-weight: bold;\n}\n\n#xhvcqolqtv .gt_font_italic {\n  font-style: italic;\n}\n\n#xhvcqolqtv .gt_super {\n  font-size: 65%;\n}\n\n#xhvcqolqtv .gt_footnote_marks {\n  font-size: 75%;\n  vertical-align: 0.4em;\n  position: initial;\n}\n\n#xhvcqolqtv .gt_asterisk {\n  font-size: 100%;\n  vertical-align: 0;\n}\n\n#xhvcqolqtv .gt_indent_1 {\n  text-indent: 5px;\n}\n\n#xhvcqolqtv .gt_indent_2 {\n  text-indent: 10px;\n}\n\n#xhvcqolqtv .gt_indent_3 {\n  text-indent: 15px;\n}\n\n#xhvcqolqtv .gt_indent_4 {\n  text-indent: 20px;\n}\n\n#xhvcqolqtv .gt_indent_5 {\n  text-indent: 25px;\n}\n\n#xhvcqolqtv .katex-display {\n  display: inline-flex !important;\n  margin-bottom: 0.75em !important;\n}\n\n#xhvcqolqtv div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {\n  height: 0px !important;\n}\n</style>\n<table class=\"gt_table\" data-quarto-disable-processing=\"false\" data-quarto-bootstrap=\"false\">\n  <caption>Mammella — Varianti germinali</caption>\n  <thead>\n    <tr class=\"gt_col_headings gt_spanner_row\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Gene\">Gene</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Variante\">Variante</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Proteina\">Proteina</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Effetto\">Effetto</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Classe\">Classe</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"ESCAT\">ESCAT</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_center\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Tier\">Tier</th>\n      <th class=\"gt_center gt_columns_top_border gt_column_spanner_outer\" rowspan=\"1\" colspan=\"2\" scope=\"colgroup\" id=\"Qualità\">\n        <div class=\"gt_column_spanner\">Qualità</div>\n      </th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"2\" colspan=\"1\" scope=\"col\" id=\"Note\">Note</th>\n    </tr>\n    <tr class=\"gt_col_headings\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"VAF\">VAF</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"Copertura\">Copertura</th>\n    </tr>\n  </thead>\n  <tbody class=\"gt_table_body\">\n    <tr><td headers=\"Gene\" class=\"gt_row gt_left\">BRCA1</td>\n<td headers=\"Variante\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Proteina\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Effetto\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Classe\" class=\"gt_row gt_left\">Pathogenic</td>\n<td headers=\"ESCAT\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Tier\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"VAF\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"Copertura\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"Note\" class=\"gt_row gt_left\">Recommend germline testing and genetic counseling.</td></tr>\n    <tr><td headers=\"Gene\" class=\"gt_row gt_left\">—</td>\n<td headers=\"Variante\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Proteina\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Effetto\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Classe\" class=\"gt_row gt_left\">No pathogenic variants suspected</td>\n<td headers=\"ESCAT\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"Tier\" class=\"gt_row gt_center\">NA</td>\n<td headers=\"VAF\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"Copertura\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"Note\" class=\"gt_row gt_left\">Germline per storia personale/familiare.</td></tr>\n  </tbody>\n  <tfoot class=\"gt_sourcenotes\">\n    <tr>\n      <td class=\"gt_sourcenote\" colspan=\"10\"><span data-qmd-base64=\"KipOb3RhKio6IFZBRiBlIGNvcGVydHVyYSBzb25vIHJpcG9ydGF0ZSBzb2xvIHNlIHByZXNlbnRpIG5laSBmaWxlIHNvcmdlbnRlLg==\"><span class='gt_from_md'><strong>Nota</strong>: VAF e copertura sono riportate solo se presenti nei file sorgente.</span></span></td>\n    </tr>\n  </tfoot>\n  \n</table>\n</div>\n```\n\n:::\n:::\n\n\n\n\n\n::: callout-note\n**Indicazioni pratiche**\\\n- *PIK3CA* **p.H1047R** → considerare **alpelisib** + ET (alternativa a capivasertib+fulvestrant in HR+/HER2− con PIK3CA).\\\n- *ESR1* patogena → **elacestrant** dopo ET/CDK4/6i.\\\n- *BRCA1/2* patogena (specialmente TNBC) → **PARP**; invio a **genetica medica** e **cascade testing**.\\\n- **PD‑L1 CPS ≥10** in TNBC → **pembrolizumab + chemio** in prima linea.\\\n- **HER2‑low** → **T‑DXd** in setting avanzato dopo almeno una chemioterapia.\n:::\n\n------------------------------------------------------------------------\n\n## Riferimenti (principali, per pronta consultazione)\n\n-   **ESMO Living Guideline (Aprile 2025) — HR+/HER2− MBC**: https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-metastatic-breast-cancer/hr-positive-her2-negative-metastatic-breast-cancer/hr-her2-mbc-progressive-disease-candidate-for-endocrine-therapy-targeted-therapy\\\n-   **FDA — Elacestrant (ESR1‑mut, ER+/HER2−)**: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer\\\n-   **FDA — Capivasertib + fulvestrant (PIK3CA/AKT1/PTEN‑alter)**: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer\\\n-   **DESTINY‑Breast04 — T‑DXd in HER2‑low**: https://www.nejm.org/doi/full/10.1056/NEJMoa2203690\\\n-   **KEYNOTE‑355 — Pembrolizumab + chemio in TNBC PD‑L1 CPS≥10**: https://pubmed.ncbi.nlm.nih.gov/35857659/\\\n-   **TROPiCS‑02 / ASCENT — Sacituzumab govitecan**: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901245-X/fulltext ; https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.1003 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12257498/",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {
      "include-in-header": [
        "<link href=\"site_libs/pagedtable-1.1/css/pagedtable.css\" rel=\"stylesheet\" />\n<script src=\"site_libs/pagedtable-1.1/js/pagedtable.js\"></script>\n"
      ]
    },
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}